Henkel vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
German consumer goods and industrial adhesive company with €21B revenue; Loctite adhesives and Schwarzkopf hair care competing with 3M and P&G through EV battery adhesive growth.
About
Henkel is a German multinational consumer goods and industrial company producing branded consumer goods (Schwarzkopf hair care, Persil laundry detergent, Dial soap, Right Guard deodorant) alongside adhesive technologies for industrial, automotive, and electronics applications. Listed on the Frankfurt Stock Exchange (XETRA: HENKY) and headquartered in Düsseldorf, Germany, Henkel generates approximately €21 billion in annual revenue through two main divisions: Adhesive Technologies (industrial and consumer adhesives, sealants, surface treatments) and Consumer Brands (hair colorants, styling products, laundry/home care).\n\nHenkel's Adhesive Technologies segment produces Loctite adhesives (a globally recognized industrial adhesive brand), BONDERITE surface treatments for automotive and aerospace metal processing, and consumer adhesives (Pritt glue sticks). This segment serves automotive manufacturers (adhesives used in EV battery assembly are a growing opportunity), electronics manufacturers, and aerospace and defense. The Consumer Brands segment includes Schwarzkopf (professional hair care sold in salons and retail), Syoss hair care, Persil laundry detergent, and Fa body care.\n\nIn 2025, Henkel is executing a strategic reorganization that merged its former Laundry & Home Care and Beauty Care divisions into a single Consumer Brands segment to improve efficiency. The Adhesive Technologies segment benefits from EV battery manufacturing growth (structural adhesives for battery packs and EV body construction are growing categories). Henkel competes with 3M, Illinois Tool Works, and Bostik for industrial adhesives, and with Procter & Gamble, Unilever, and Revlon for consumer goods. The 2025 strategy emphasizes driving Adhesive Technologies growth through EV and semiconductor manufacturing adhesive applications.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.